Imagion Biosystems (ASX:IBX) Clears Central IRB Ethics Approval, Advancing MagSense Phase 2 Trial Toward Patient Enrolment

Sonal Goyal

30 September 2026 12:39 PM AEST

Imagion Biosystems (ASX:IBX) Clears Central IRB Ethics Approval, Advancing MagSense Phase 2 Trial Toward Patient Enrolment

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Advarra IRB granted central ethics approval for IBX's Phase 1b/2 MagSense HER2 imaging trial in the United States.

• The approval covers all study materials including the protocol and informed consent forms, enabling active site initiation.

• A single central IRB process is being used to streamline multi-site activation and patient enrolment.

• Combined with existing FDA IND clearance, IBX now holds all key regulatory approvals required to commence the US trial.

Imagion Biosystems Limited (ASX:IBX), a clinical-stage medical imaging company focused on cancer diagnostics, announced on 30 September 2026 that Advarra, Inc. has granted central Institutional Review Board (IRB) ethics approval for its Phase 1b/2 clinical trial of the MagSense HER2 Imaging Agent. The milestone removes a key regulatory barrier and positions the company to move into active site initiation and, subsequently, patient enrolment.

About Imagion Biosystems

Imagion Biosystems is a Melbourne-based clinical-stage company developing MagSense, a proprietary class of MRI imaging agents that use targeted magnetic nanoparticles to detect cancer without ionising radiation or radioactive tracers. The company's lead product targets HER2-positive breast cancer, specifically the detection of nodal metastases, and has successfully completed a Phase 1 study. The MagSense platform also holds potential application in prostate and ovarian cancers.

Central IRB Approval: What It Means

The Advarra IRB's review confirmed that the study protocol, informed consent processes, and participant safeguards all meet United States ethical and regulatory standards for clinical research involving human participants. This central IRB model is designed to allow multiple participating clinical sites to rely on a single ethics review rather than conducting separate institutional reviews, reducing duplication and accelerating site activation timelines.

This approval, when combined with the previously announced FDA Investigational New Drug (IND) clearance, means Imagion now holds the full suite of regulatory and ethics approvals required to begin the trial in the United States.

Trial Design and Stage of Progress

The MagSense Phase 1b/2 trial is evaluating the imaging agent in HER2-positive breast cancer patients. According to the company, site contract execution, investigator training, and patient recruitment planning are now underway. First patient enrolment is expected to commence following first site activation.

Ward Detwiler, President of Imagion's US operations, noted that focus now remains on completing the final stages of site activation before opening the study for patient enrolment. The trial represents a material step in the company's clinical development program, as generating Phase 2 efficacy and safety data is central to advancing MagSense toward commercial potential.

Technology and Market Context

MagSense technology is positioned as a differentiated approach to cancer imaging. Conventional imaging methods cannot reliably distinguish benign tumours from malignant cancer. MagSense agents aim to improve diagnostic precision through molecular specificity, using targeted magnetic nanoparticles visible under MRI — without the use of radioactive tracers, which differentiates it from several existing nuclear medicine-based imaging agents.

The company has developed MagSense applications for three cancer types to date, with HER2-positive breast cancer being the most advanced in clinical development.

Key Takeaways

Imagion Biosystems has reached a meaningful regulatory milestone with the receipt of central IRB ethics approval from Advarra. Combined with FDA IND clearance already in place, the company is now positioned to begin active site initiation and move toward patient enrolment in its Phase 1b/2 MagSense trial. The coming months will be defined by the pace of site contracting and the speed at which the first participants are enrolled, with Phase 2 efficacy and safety data generation representing the next substantive clinical objective.

FAQs

Q: What did Imagion Biosystems announce on 30 September 2026?

A: IBX announced that Advarra, Inc. granted central Institutional Review Board (IRB) ethics approval for its Phase 1b/2 clinical trial of the MagSense HER2 Imaging Agent in the United States.

Q: What is MagSense technology?

A: MagSense is a class of MRI imaging agents that use targeted magnetic nanoparticles to potentially detect cancers without ionising radiation or radioactive tracers, offering molecular specificity beyond conventional imaging.

Q: What regulatory approvals does IBX now hold for the trial?

A: Imagion holds both FDA Investigational New Drug (IND) clearance and central IRB ethics approval from Advarra, covering the key US regulatory and ethics requirements to begin the trial.

Q: What does central IRB approval mean for site activation?

A: A central IRB allows multiple trial sites to rely on a single ethics review, reducing duplication and accelerating the process of activating clinical sites for patient enrolment.

Q: What are the next steps for the Phase 1b/2 trial?

A: The company is finalising site contract execution, investigator training, and patient recruitment planning, with first patient enrolment expected to commence following first site activation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.